As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event ... as there is no increased safety risk or less efficacy. Celltrion was next to announce the ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
AbbVie’s promising pipeline and 3.95% dividend yield offer growth potential. Read why ABBV stock could thrive despite the Emraclidine trial failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback